Cargando…

Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic Development

Hypoxia is one of the most common phenotypes of malignant tumours. Hypoxia leads to the increased activity of hypoxia-inducible factors (HIFs), which regulate the expression of genes controlling a raft of pro-tumour phenotypes. These include maintenance of the cancer stem cell compartment, epithelia...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Jie, Byrne, Niall M., Al Jamal, Wafa, Coulter, Jonathan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966647/
https://www.ncbi.nlm.nih.gov/pubmed/31835751
http://dx.doi.org/10.3390/cancers11121989
_version_ 1783488784358178816
author Feng, Jie
Byrne, Niall M.
Al Jamal, Wafa
Coulter, Jonathan A.
author_facet Feng, Jie
Byrne, Niall M.
Al Jamal, Wafa
Coulter, Jonathan A.
author_sort Feng, Jie
collection PubMed
description Hypoxia is one of the most common phenotypes of malignant tumours. Hypoxia leads to the increased activity of hypoxia-inducible factors (HIFs), which regulate the expression of genes controlling a raft of pro-tumour phenotypes. These include maintenance of the cancer stem cell compartment, epithelial-mesenchymal transition (EMT), angiogenesis, immunosuppression, and metabolic reprogramming. Hypoxia can also contribute to the tumour progression in a HIF-independent manner via the activation of a complex signalling network pathway, including JAK-STAT, RhoA/ROCK, NF-κB and PI3/AKT. Recent studies suggest that nanotherapeutics offer a unique opportunity to target the hypoxic microenvironment, enhancing the therapeutic window of conventional therapeutics. In this review, we summarise recent advances in understanding the impact of hypoxia on tumour progression, while outlining possible nanotherapeutic approaches for overcoming hypoxia-mediated resistance.
format Online
Article
Text
id pubmed-6966647
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69666472020-02-04 Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic Development Feng, Jie Byrne, Niall M. Al Jamal, Wafa Coulter, Jonathan A. Cancers (Basel) Review Hypoxia is one of the most common phenotypes of malignant tumours. Hypoxia leads to the increased activity of hypoxia-inducible factors (HIFs), which regulate the expression of genes controlling a raft of pro-tumour phenotypes. These include maintenance of the cancer stem cell compartment, epithelial-mesenchymal transition (EMT), angiogenesis, immunosuppression, and metabolic reprogramming. Hypoxia can also contribute to the tumour progression in a HIF-independent manner via the activation of a complex signalling network pathway, including JAK-STAT, RhoA/ROCK, NF-κB and PI3/AKT. Recent studies suggest that nanotherapeutics offer a unique opportunity to target the hypoxic microenvironment, enhancing the therapeutic window of conventional therapeutics. In this review, we summarise recent advances in understanding the impact of hypoxia on tumour progression, while outlining possible nanotherapeutic approaches for overcoming hypoxia-mediated resistance. MDPI 2019-12-11 /pmc/articles/PMC6966647/ /pubmed/31835751 http://dx.doi.org/10.3390/cancers11121989 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Feng, Jie
Byrne, Niall M.
Al Jamal, Wafa
Coulter, Jonathan A.
Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic Development
title Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic Development
title_full Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic Development
title_fullStr Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic Development
title_full_unstemmed Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic Development
title_short Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic Development
title_sort exploiting current understanding of hypoxia mediated tumour progression for nanotherapeutic development
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966647/
https://www.ncbi.nlm.nih.gov/pubmed/31835751
http://dx.doi.org/10.3390/cancers11121989
work_keys_str_mv AT fengjie exploitingcurrentunderstandingofhypoxiamediatedtumourprogressionfornanotherapeuticdevelopment
AT byrneniallm exploitingcurrentunderstandingofhypoxiamediatedtumourprogressionfornanotherapeuticdevelopment
AT aljamalwafa exploitingcurrentunderstandingofhypoxiamediatedtumourprogressionfornanotherapeuticdevelopment
AT coulterjonathana exploitingcurrentunderstandingofhypoxiamediatedtumourprogressionfornanotherapeuticdevelopment